Biotech Startups
9,866 companies tagged Biotech, with their investors and founders.
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.
3 investors
NK:IO develops natural killer (NK) cell and small molecule therapies for cancer, targeting both haematological and solid tumours such as ovarian cancer. Its platform technologies, based on umbilical cord blood stem cells, aim to expand NK cells and enhance their tumour-killing capacity for cancer immunotherapy, with programmes at the research and early preclinical stage.
3 investors
NorthSea Therapeutics is a late-stage clinical biotechnology company developing structurally engineered fatty acids (SEFAs) as oral treatments for metabolic, cholestatic, and fibrotic diseases. Its pipeline targets conditions such as intestinal failure-associated liver disease, severe hypertriglyceridemia, and metabolic dysfunction-associated steatohepatitis.
3 investors
Novadip develops regenerative medicine treatments using its 3M3 tissue regeneration platform to address conditions requiring bone and tissue repair, including spinal fusion, cancer recovery, and complex fractures.
3 investors
Novel Microdevices develops a portable, battery-powered point-of-care molecular diagnostic system that runs PCR-based nucleic acid amplification on disposable cartridges to detect pathogens and antibiotic-resistance mutations in about 15 minutes. The system targets same-visit testing and diagnosis, with an emphasis on low-resource settings and low- and middle-income countries.
3 investors
Novogaia develops novel medicines derived from fungi by using machine learning to identify drug-like molecular structures from natural samples and match them to targets addressing unmet medical needs.
3 investors
NOVOS is a longevity biotechnology company that develops science-validated supplement formulations and aging assessment tools designed to target the biological mechanisms of aging rather than disease symptoms. The company serves consumers seeking to extend healthspan through evidence-based products backed by clinical trials and mechanistic research.
3 investors
Quince Therapeutics is a clinical-stage biopharmaceutical company developing eDSP, an investigational therapy studied in a Phase 3 clinical trial (NEAT) for patients with Ataxia-Telangiectasia (A-T). The company focuses on treatments for rare and debilitating diseases.
3 investors
NOWDiagnostics develops rapid, point-of-care and consumer diagnostic tests. The company operates in the medical diagnostics and MedTech industry.
3 investors
Nucleix is a healthcare company developing diagnostic technology based on DNA/nucleic acid analysis for cancer detection. It serves the medical diagnostics and biotechnology market.
3 investors
Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
3 investors
Nuevocor is a biotechnology company developing gene therapy treatments for cardiovascular and metabolic diseases. The company leverages innovative cell biology and gene therapy technologies to address genetic and acquired cardiac conditions.
3 investors
Numen develops at-home cancer diagnostics and health data collection infrastructure using machine learning models to enable earlier intervention and improve patient outcomes.
3 investors
Nura Bio develops neuroprotective medicines targeting neurological diseases by translating scientific advances in axonal degeneration and neuroimmune regulation into novel therapeutics.
3 investors
RNA therapeutics company with a chip-based mRNA manufacturing platform; acquired by Medici Therapeutics in November 2025.
3 investors
A nutrition technology company that uses wild-type unicellular aquatic organisms to produce protein- and fiber-rich, non-GMO ingredients (marketed as Marine Whey) for food applications. It partners with global food corporations to deliver affordable nutrition, with a focus on the Global South.
3 investors
Nutromics is developing a wearable patch for continuous, real-time monitoring of biomarkers in hospital settings, starting with therapeutic drug monitoring of the antibiotic vancomycin. The technology aims to help clinicians keep patients within the therapeutic range and is intended to expand into infectious disease, cardiology, and renal indications.
3 investors
Nuwellis develops medical technology solutions for managing fluid overload in patients with cardiorenal conditions, serving clinicians and healthcare providers in inpatient and outpatient settings. The company focuses on treating the interconnection between heart and kidney function to improve patient outcomes and accelerate recovery.
3 investors
NX Prenatal is a molecular diagnostics company developing exosome-based liquid biopsy assays that detect adverse pregnancy conditions such as preterm birth, preeclampsia, and placenta accreta. Its non-invasive tests help physicians identify at-risk pregnancies to intervene and reduce complications for mother and child.
3 investors
Nyra Medical develops the CARLEN (Cardiac Leaflet Enhancer) system, a transcatheter single-leaflet device for repairing functional mitral regurgitation while preserving native valve function. It targets both TEER-suitable patients and those with limited existing treatment options in the cardiology/medical device field.
3 investors
NZeno develops porcine (pig) cell-based therapeutics and xenotransplantation technologies, building on work in encapsulated cell therapies and breeding pigs certified as tissue sources for human transplantation. The company operates in the biotechnology and regenerative medicine field.
3 investors
Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.
3 investors
OCON Medical develops intrauterine devices for gynecological conditions, including non-hormonal contraception and treatments for abnormal uterine bleeding. The company's products serve women seeking alternatives to hormonal methods and surgical interventions.
3 investors
Octagon Therapeutics is a biotech company developing new medicines for autoimmune diseases with unmet clinical need, based on scientific research from Harvard. It serves patients living with autoimmunity through its drug development programs.
3 investors